**MED: Annual General Mandate 2024**

On June 26, 2024, Mediplantex National Pharmaceutical Joint Stock Company announced General Mandate No. 01/2024/NQ-DHDCD/MED as follows:

Article 1. Approve the Reports:

* Report of the Board of Directors on the activities results of the Board of Directors in 2023, term 2020 - 2024 and orientation for implementing production and business plan for 2024, term 2024 - 2029;
* Report of the General Manager on production and business results in 2023 and orientation for implementing the production and business plan for 2024

The results achieved:

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No. | Targets | Unit | Plan 2023 | Results 2023 | Results 2022 | Results/Plan 2023 (%) | Results 2023/ 2022 (%) |
| I | Industrial production | Product unit | 622,567,400 | 572,700,000 | 766,870,000 | 92.0% | 74.7% |
| Factory No. 1 | Product unit | 78,479,400 | 79,500,000 | 90,860,000 | 101.3% | 87.5% |
| Factory No. 2 | Product unit | 544,088,000 | 493,200,000 | 676,010,000 | 90.6% | 73.0% |
| II | The whole company | | |  |  |  |  |
| 1 | Total revenue | VND | 398,490,018,564 | 402,741,168,246 | 401,051,153,746 | 101.1% | 100.4% |
| 2 | Total cost of goods sale | VND | 320,152,481,989 | 319,663,181,403 | 322,634,868,027 | 99.8% | 99.1% |
| 3 | Gross profit | VND | 78,337,536,575 | 83,077,986,843 | 78,416,285,719 | 106.1% | 105.9% |
| 4 | Revenue from financial activities | VND | 2,500,000,000 | 7,850,684,606 | 5,902,051,774 | 314.0% | 133.0% |
| 5 | Financial expenses | VND | 5,000,000,000 | 6,710,009,669 | 7,544,213,916 | 134.2% | 88.9% |
| 6 | Selling expenses | VND | 12,965,200,000 | 12,728,342,594 | 14,421,095,229 | 98.2% | 88.3% |
| 7 | General and administrative expense | VND | 50,396,253,460 | 56,168,632,749 | 54,909,423,457 | 111.5% | 102.3% |
| III | Profit before tax | VND | 12,476,083,115 | 14,923,064,957 | 8,236,313,246 | 119.6% | 181.2% |

* The Report of the Supervisory Board on the activities results for the term 2020-2024 and operating orientation for the term 2024-2029;

Plan on production and business 2024:

|  |  |  |  |
| --- | --- | --- | --- |
| No. | Targets | Unit | Amount |
| I | Industrial production | Product unit | 635,386,000 |
| 1 | Factory No. 1 | Product unit | 86,413,000 |
| 2 | Factory No. 2 | Product unit | 548,973,000 |
| II | Total sale value | VND | 360,724,200,700 |
| III | Cost of goods sale | VND | 280,114,838,340 |
| IV | Total gross profit | VND | 80,609,362,360 |
| V | Total selling expenses | VND | 8,800,000,000 |
| VI | Revenue from service provision | VND | 500,000,000 |
|  | Financial expenses | VND | 7,500,000,000 |
| VII | Administrative expenses | VND | 48,692,066,920 |
| VIII | Profit before tax | VND | 16,117,295,440 |

Article 2. Approve the Audited Financial Statements 2023.

Article 3. Approve the selection of an independent audit company for the Financial Statements 2024

Article 4. Approve the Plan for profit distribution and dividend payment in 2023 and propose the Plan for profit distribution and dividend payment in 2024;

Plan on profit distribution and dividend payment in 2023:

|  |  |  |
| --- | --- | --- |
| Targets | Rate (%) | Value (Unit: VND) |
| 1 Profit before tax 2023 |  | 14,923,064,957 |
| 2. Payable Corporate Income tax 2023 |  | 3,179,172,606 |
| 3. Profit after tax 2023 |  | 11,743,892,351 |
| 4. Profit distribution 2023 |  | 11,743,892,351 |
| 4.1. Appropriation for bonus for the Executive Board |  | 205,590,000 |
| Bonus for achieving profit plan | 7% | 117,440,000 |
| Additional bonus of 5% of profit value exceeding plan |  | 88,150,000 |
| 4.2. Appropriation for bonus for the Board of Directors and the Supervisory Board |  | 205,590,000 |
| Bonus for achieving profit plan | 1% | 117,440,000 |
| Additional bonus of 05% of profit value exceeding plan |  | 88,150,000 |
| 4.3. Appropriation for investment and development fund | 0% |  |
| 4.4. The remaining profit for dividend payment |  | 11,332,712,351 |
| 5 Retained profit of previous years |  | 340,211,037 |
| 6. Total profits paid dividends until the end of 2023 |  | 11,672,923,388 |
| 7. Proposal to pay dividends | 9% of charter capital | 11,169,000,000 |
| 8. Retained profit in 2024 |  | 503,923,388 |

Plan on using profit 2024, the dividend payment rate 2024:

|  |  |  |
| --- | --- | --- |
| Expected 2024 | Rate (%) | Value VND |
| I. Profit before tax 2024 |  | 16,117,295,440 |
| II. Profit after tax 2024 |  | 12,893,836,352 |
| 1 Appropriation for bonus for the Executive Board | 1% | 128,938,363 |
| 2. Appropriation for bonuses for the Board of Directors and the Supervisory Board | 1% | 128,938,363 |
| 3. Appropriation for investment and development fund | 0 |  |
| 4. The remaining profit for dividend payment | 9% of charter capital | 11,169,000,000 |
| 5. Retained profit in 2025 |  | 1,466,959,626 |

Article 5. Approve the remuneration of the Board of Directors and the Supervisory Board in 2024.

‎‎Article 6. Approve the capital mobilization plan and increase the total investment capital at the project "Pharmaceutical Science and Technology Center and pharmaceutical production application factory meeting EU GMP standards".

Article 7. Approve the end of the 2020 - 2025 term of the Board of Directors and electing members of the Board of Directors for the 2024-2029 term.

The General Meeting of Shareholders elected and listed 05 members of the Board of Directors elected for the 2024 - 2029 term including:

* Mr. Tran Hoang Dung- Member of the Board of Directors
* Mr. Tran Nguyen Hoang An- Member of the Board of Directors
* Mr. Tran Xuan Dinh- Member of the Board of Directors
* Mr. Thai Khac Minh- Member of the Board of Directors
* Ms. Nguyen Thi Thuy- Member of the Board of Directors

Article 8: Approve the end of the 2020 - 2025 term of the Supervisory Board and elect members of the Supervisory Board for the 2024 - 2029 term.

The General Meeting of Shareholders elected and listed 03 members of the Supervisory Board elected for the 2024 - 2029 term including:

* Mr. Ho Ngoc Tuan- Member of the Supervisory Board
* Ms. Ha Thi Bich Hanh - Member of the Supervisory Board
* Ms. Do Ngoc Thuy - Member of the Supervisory Board

Article 9: Approve amending and supplementing the Charter and Internal regulations on corporate governance of Mediplantex National Pharmaceutical Joint Stock Company.

This General Mandate takes effect from the date of its promulgation. The Board of Directors, the Supervisory Board, the Board of Management and related departments are responsible for implementing this General Mandate.